Intranasal drug delivery to the brain

AAPS Advances in the Pharmaceutical Sciences Series

Volumn 10, Issue , 2014, Pages 401-431

  Lochhead, Jeffrey J ^a   Thorne, Robert G ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DAVUNETIDE; INSULIN; LOSARTAN; MELANOCORTIN; OXYTOCIN; REMOXIPRIDE;

ARTICLE; BLOOD BRAIN BARRIER; BRAIN; CLINICAL TRIAL (TOPIC); CRANIAL NERVE; DRUG TARGETING; DRUG TRANSPORT; FIRST PASS EFFECT; GENE VECTOR; HUMAN; INTRANASAL DRUG ADMINISTRATION; NONHUMAN; NOSE; NOSE MUCOSA; OLFACTORY EPITHELIUM; OLFACTORY NERVE; PRIORITY JOURNAL; TRIGEMINAL NERVE;

EID: 85081148388     PISSN: 22107371     EISSN: 2210738X     Source Type: Book Series    
DOI: 10.1007/978-1-4614-9105-7_14     Document Type: Article

References (125)

1. Altner H, Altner-Kolnberger I (1974) Freeze-fracture and tracer experiments on the permeability of the zonulae occludentes in the olfactory mucosa of vertebrates. Cell Tissue Res 154(1): 51–59
2. Anton F, Peppel P (1991) Central projections of trigeminal primary afferents innervating the nasal mucosa: a horseradish peroxidase study in the rat. Neuroscience 41(2–3):617–628
3. Baier PC, Hallschmid M, Seeck-Hirschner M, Weinhold SL, Burkert S, Diessner N, Goder R, Aldenhoff JB, Hinze-Selch D (2011) Effects of intranasal hypocretin-1 (orexin A) on sleep in narcolepsy with cataplexy. Sleep Med 12(10):941–946
4. Baier PC, Weinhold SL, Huth V, Gottwald B, Ferstl R, Hinze-Selch D (2008) Olfactory dysfunction in patients with narcolepsy with cataplexy is restored by intranasal Orexin A (Hypocretin-1).Brain 131(Pt 10):2734–2741
5. Baker H, Genter MB (2003) The olfactory system and the nasal mucosa as portals of entry of viruses, drugs, and other exogenous agents into the brain. In: Doty RL (ed) Handbook of olfaction and gustation, 2nd edn. Marcel Dekker, Inc., New York, pp 549–573
6. Baker H, Spencer RF (1986) Transneuronal transport of peroxidase-conjugated wheat germ agglutinin (WGA-HRP) from the olfactory epithelium to the brain of the adult rat. Exp Brain Res 63(3):461–473
7. Banks WA (2004) Are the extracellular pathways a conduit for the delivery of therapeutics to the brain? Curr Pharm Des 10(12):1365–1370
8. Banks WA (2009) Characteristics of compounds that cross the blood-brain barrier. BMC Neurol9(Suppl 1):S3
9. Bilston LE, Fletcher DF, Brodbelt AR, Stoodley MA (2003) Arterial pulsation-driven cerebrospinal fl uid fl ow in the perivascular space: a computational model. Comput Methods Biomech Biomed Engin 6(4):235–241
10. Bojsen-Moller F (1975) Demonstration of terminalis, olfactory, trigeminal and perivascular nerves in the rat nasal septum. J Comp Neurol 159(2):245–256
11. Born J, Lange T, Kern W, McGregor GP, Bickel U, Fehm HL (2002) Sniffi ng neuropeptides: a transnasal approach to the human brain. Nat Neurosci 5(6):514–516
12. Bradbury MWB, Cserr HF (1985) Drainage of cerebral interstitial fl uid and of cerebrospinal fl uid into lymphatics. In: Johnston MG (ed) Experimental biology of the lymphatic circulation, vol9. Elsevier, Amsterdam and New York, pp 355–391
13. Broadwell RD, Balin BJ (1985) Endocytic and exocytic pathways of the neuronal secretory process and trans-synaptic transfer of wheat germ agglutinin-horseradish peroxidase in vivo.J Comp Neurol 242(4):632–650
14. Broberg EK, Peltoniemi J, Nygardas M, Vahlberg T, Roytta M, Hukkanen V (2004) Spread and replication of and immune response to gamma134.5-negative herpes simplex virus type 1 vectors in BALB/c mice. J Virol 78(23):13139–13152
15. Butt AM, Jones HC, Abbott NJ (1990) Electrical resistance across the blood-brain barrier in anaesthetized rats: a developmental study. J Physiol 429:47–62
16. Buchner K, Seitz-Tutter D, Shonitzer K, Weiss DG (1987) A quantitative study of anterograde and retrograde axonal transport of exogenous proteins in olfactory nerve C-fi bers. Neuroscience22:697–707
17. Caggiano M, Kauer JS, Hunter DD (1994) Globose basal cells are neuronal progenitors in the olfactoryepithelium: a lineage analysis using a replication-incompetent retrovirus. Neuron 13(2):339–352
18. Carmichael ST, Clugnet MC, Price JL (1994) Central olfactory connections in the macaque monkey. J Comp Neurol 346(3):403–434
19. Cattepoel S, Hanenberg M, Kulic L, Nitsch RM (2011) Chronic intranasal treatment with an anti- abeta(30-42) scFv antibody ameliorates amyloid pathology in a transgenic mouse model of Alzheimer’s disease. PLoS One 6(4):e18296
20. Cauna N, Hinderer KH (1969) Fine structure of blood vessels of the human nasal respiratory mucosa. Ann Otol Rhinol Laryngol 78(4):865–879
21. Charlton ST, Whetstone J, Fayinka ST, Read KD, Illum L, Davis SS (2008) Evaluation of direct transport pathways of glycine receptor antagonists and an angiotensin antagonist from the nasal cavity to the central nervous system in the rat model. Pharm Res 25(7):1531–1543
22. Costantino HR, Illum L, Brandt G, Johnson PH, Quay SC (2007) Intranasal delivery: physico-chemical and therapeutic aspects. Int J Pharm 337(1–2):1–24
23. Coyle P (1975) Arterial patterns of the rat rhinencephalon and related structures. Exp Neurol 49:671–690
24. Craft S, Baker LD, Montine TJ, Minoshima S, Watson GS, Claxton A, Arbuckle M, Callaghan M, Tsai E, Plymate SR, Green PS, Leverenz J, Cross D, Gerton B (2012) Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch Neurol 69(1):29–38
25. Crone C, Olesen SP (1982) Electrical resistance of brain microvascular endothelium. Brain Res241(1):49–55
26. Danielyan L, Klein R, Hanson LR, Buadze M, Schwab M, Gleiter CH, Frey WH (2010) Protective effects of intranasal losartan in the APP/PS1 transgenic mouse model of Alzheimer disease.Rejuvenation Res 13(2–3):195–201
27. Danielyan L, Schafer R, von Ameln-Mayerhofer A, Bernhard F, Verleysdonk S, Buadze M, Lourhmati A, Klopfer T, Schaumann F, Schmid B, Koehle C, Proksch B, Weissert R, Reichardt HM, van den Brandt J, Buniatian GH, Schwab M, Gleiter CH, Frey WH II (2011) Therapeutic effi cacy of intranasally delivered mesenchymal stem cells in a rat model of Parkinson disease.Rejuvenation Res 14(1):3–16. doi: 10.1089/rej.2010.1130
28. Danielyan L, Schafer R, von Ameln-Mayerhofer A, Buadze M, Geisler J, Klopfer T, Burkhardt U, Proksch B, Verleysdonk S, Ayturan M, Buniatian GH, Gleiter CH, Frey WH II (2009) Intranasal delivery of cells to the brain. Eur J Cell Biol 88(6):315–324
29. Davis SS, Illum L (2003) Absorption enhancers for nasal drug delivery. Clin Pharmacokinet42(13):1107–1128
30. Deadwyler SA, Porrino L, Siegel JM, Hampson RE (2007) Systemic and nasal delivery of orexin- A (Hypocretin-1) reduces the effects of sleep deprivation on cognitive performance in nonhuman primates. J Neurosci 27(52):14239–14247
31. Deatly AM, Haase AT, Fewster PH, Lewis E, Ball MJ (1990) Human herpes virus infections and Alzheimer’s disease. Neuropathol Appl Neurobiol 16(3):213–223
32. Deli MA (2009) Potential use of tight junction modulators to reversibly open membranous barriers and improve drug delivery. Biochim Biophys Acta 1788:892–910
33. Dhuria S V, Hanson LR, Frey WH II (2009) Intranasal drug targeting of hypocretin-1 (orexin-A) to the central nervous system. J Pharm Sci 98(7):2501–251
34. Dhuria S V, Hanson LR, Frey WH II (2010) Intranasal delivery to the central nervous system: mechanisms and experimental considerations. J Pharm Sci 99(4):1654–1673
35. Donega V, van Velthoven CT, Nijboer CH, van Bel F, Kas MJ, Kavelaars A, Heijnen CJ (2013) Intranasal mesenchymal stem cell treatment for neonatal brain damage: long-term cognitive and sensorimotor improvement. PLoS One 8(1):e51253
36. Doty RL (2008) The olfactory vector hypothesis of neurodegenerative disease: is it viable? Ann Neurol 63(1):7–15
37. Draghia R, Caillaud C, Manicom R, Pavirani A, Kahn A, Poenaru L (1995) Gene delivery into the central nervous system by nasal instillation in rats. Gene Ther 2(6):418–423
38. Elsaesser R, Paysan J (2007) The sense of smell, its signalling pathways, and the dichotomy of cilia and microvilli in olfactory sensory cells. BMC Neurosci 8(Suppl 3):S1
39. Ermisch A, Barth T, Ruhle HJ, Skopkova J, Hrbas P, Landgraf R (1985) On the blood-brain barrier to peptides: accumulation of labelled vasopressin, DesGlyNH2-vasopressin and oxytocin by brain regions. Endocrinol Exp 19(1):29–37
40. Faber WM (1937) The nasal mucosa and the subarachnoid space. Am J Anat 62(1):121–148
41. Favre JJ, Chaffanjon P, Passagia JG, Chirossel JP (1995) Blood supply of the olfactory nerve: meningeal relationships and surgical relevance. Surg Radiol Anat 17:133–138
42. Febbraro F, Andersen KJ, Sanchez-Guajardo V, Tentillier N, Romero-Ramos M (2013) Chronic intranasal deferoxamine ameliorates motor defects and pathology in the alpha-synuclein Raav Parkinson’s model. Exp Neurol 247C:45–58
43. Field P, Li Y, Raisman G (2003) Ensheathment of the olfactory nerves in the adult rat. J Neurocytol32(3):317–324
44. Finger TE, St Jeor VL, Kinnamon JC, Silver WL (1990) Ultrastructure of substance P- and CGRP-immunoreactive nerve fi bers in the nasal epithelium of rodents. J Comp Neurol 294(2): 293–305
45. Francis GJ, Martinez JA, Liu WQ, Xu K, Ayer A, Fine J, Tuor UI, Glazner G, Hanson LR, Frey WH II, Toth C (2008) Intranasal insulin prevents cognitive decline, cerebral atrophy and white matter changes in murine type I diabetic encephalopathy. Brain 131(Pt 12):3311–3334
46. Fransson M, Piras E, Burman J, Nilsson B, Essand M, Lu B, Harris RA, Magnusson PU, Brittebo E, Loskog AS (2012) CAR/FoxP3-engineered T regulatory cells target the CNS and suppress EAE upon intranasal delivery. J Neuroinfl ammation 9:112
47. Frenkel D, Solomon B (2002) Filamentous phage as vector-mediated antibody delivery to the brain. Proc Natl Acad Sci U S A 99(8):5675–5679
48. Frey WH II, Liu L, Chen XQ, Thorne RG, Fawcett JR, Ala TA, Rahman YE (1997) Delivery of 125I-NGF to the brain via the olfactory route. Drug Deliv 4:87–92
49. Gozes I, Giladi E, Pinhasov A, Bardea A, Brenneman DE (2000) Activity-dependent neurotrophic factor: intranasal administration of femtomolar-acting peptides improve performance in a water maze. J Pharmacol Exp Ther 293(3):1091–1098
50. Graff CL, Pollack GM (2005) Nasal drug administration: potential for targeted central nervous system delivery. J Pharm Sci 94:1187–1195
51. Standring S, Borley NR, Collins P, Crossman AR, Gatzoulis MA, Healy JC, Johnson D, Mahadevan V, Newell RLM, Wigley CB (2008) Gray’s anatomy, 40 edn. Elsevier, Philadelphia
52. Greene EC (1935) Anatomy of the rat. Braintree Scientifi c, inc., Braintree, MA
53. Guo C, Wang T, Zheng W, Shan ZY, Teng WP, Wang ZY (2013) Intranasal deferoxamine reverses iron-induced memory defi cits and inhibits amyloidogenic APP processing in a transgenic mouse model of Alzheimer’s disease. Neurobiol Aging 34(2):562–5759
54. Hadaczek P, Yamashita Y, Mirek H, Tamas L, Bohn MC, Noble C, Park JW, Bankiewicz K (2006) The “perivascular pump” driven by arterial pulsation is a powerful mechanism for the distribution of therapeutic molecules within the brain. Mol Ther 14(1):69–78
55. Han IK, Kim MY, Byun HM, Hwang TS, Kim JM, Hwang KW, Park TG, Jung WW, Chun T, Jeong GJ, Oh YK (2007) Enhanced brain targeting effi ciency of intranasally administered plasmid DNA: an alternative route for brain gene therapy. J Mol Med 85(1):75–83
56. Hanson LR, Roeytenberg A, Martinez PM, Coppes VG, Sweet DC, Rao RJ, Marti DL, Hoekman JD, Matthews RB, Frey WH II, Panter SS (2009) Intranasal deferoxamine provides increased brain exposure and signifi cant protection in rat ischemic stroke. J Pharmacol Exp Ther330(3):679–686
57. Harkema JR, Carey SA, Wagner JG (2006) The nose revisited: a brief review of the comparative structure,function, and toxicologic pathology of the nasal epithelium. Toxicol Pathol 34(3):252–269
58. Hegg CC, Irwin M, Lucero MT (2009) Calcium store-mediated signaling in sustentacular cells of the mouse olfactory epithelium. Glia 57(6):634–644
59. Hillyer JF, Albrecht RM (2001) Gastrointestinal persorption and tissue distribution of differently sized colloidal gold nanoparticles. J Pharm Sci 90(12):1927–1936
60. Hoekman JD, Ho RJ (2011) Enhanced analgesic responses after preferential delivery of morphine and fentanyl to the olfactory epithelium in rats. Anesth Analg 113(3):641–651
61. Hosoya K, Kubo H, Natsume H, Sugibayashi K, Morimoto Y, Yamashita S (1993) The structural barrier of absorptive mucosae: site difference of the permeability of fl uorescein isothiocyanate-labelled dextran in rabbits. Biopharm Drug Dispos 14(8):685–695
62. Ichimura T, Fraser PA, Cserr HF (1991) Distribution of extracellular tracers in perivascular spaces of the rat brain. Brain research 545(1–2):103–113
63. Iliff JJ, Wang M, Liao Y, Plogg BA, Peng W, Gundersen GA, Benveniste H, Vates GE, Deane R, Goldman SA, Nagelhus EA, Nedergaard M (2012) A paravascular pathway facilitates CSF fl ow through the brain parenchyma and the clearance of interstitial solutes, including amyloid beta. Sci Transl Med 4(147):147ra111
64. Illum L (2004) Is nose-to-brain transport of drugs in man a reality? J Pharm Pharmacol56(1):3–17
65. Illum L (2012) Nasal drug delivery—recent developments and future prospects. J Control Release161(2):254–263
66. Iwai N, Zhou Z, Roop DR, Behringer RR (2008) Horizontal basal cells are multipotent progenitors in normal and injured adult olfactory epithelium. Stem Cells 26(5):1298–1306
67. Jafek BW (1983) Ultrastructure of human nasal mucosa. Laryngoscope 93(12):1576–1599
68. Jansson B, Bjork E (2002) Visualization of in vivo olfactory uptake and transfer using fl uorescein dextran. J Drug Target 10(5):379–386
69. Jauch-Chara K, Friedrich A, Rezmer M, Melchert UH, Scholand-Engler HG, Hallschmid M, Oltmanns KM (2012) Intranasal insulin suppresses food intake via enhancement of brain energy levels in humans. Diabetes 61(9):2261–2268
70. Jin Y, Dons L, Kristensson K, Rottenberg ME (2001) Neural route of cerebral Listeria monocyto-genes murine infection: role of immune response mechanisms in controlling bacterial neuroin-vasion. Infect Immun 69(2):1093–1100
71. Johnson NJ, Hanson LR, Frey WH (2010) Trigeminal pathways deliver a low molecular weight drug from the nose to the brain and orofacial structures. Mol Pharm 7(3):884–893
72. Johnston M, Zakharov A, Papaiconomou C, Salmasi G, Armstrong D (2004) Evidence of connections between cerebrospinal fl uid and nasal lymphatic vessels in humans, non-human primates and other mammalian species. Cerebrospinal Fluid Res 1(1):2
73. Kandimalla KK, Donovan MD (2005) Localization and differential activity of p-glycoprotein in the bovine and nasal respiratory mucosae. Pharm Res 22:1121–1128
74. Kang YS, Park JH (2000) Brain uptake and the analgesic effect of oxytocin—its usefulness as an analgesic agent. Arch Pharm Res 23(4):391–395
75. Kerjaschki D, Horander H (1976) The development of mouse olfactory vesicles and their cell contacts: a freeze-etching study. J Ultrastruct Res 54(3):420–444
76. Kida S, Pantazis A, Weller RO (1993) CSF drains directly from the subarachnoid space into nasal lymphatics in the rat. Anatomy, histology and immunological signifi cance. Neuropathol Appl Neurobiol 19(6):480–488
77. Kim ID, Kim SW, Lee JK (2009) Gene knockdown in the olfactory bulb, amygdala, and hypothalamusby intranasal siRNA administration. Korean J Anat 42(4):285–292
78. Kiyono H, Fukuyama S (2004) NALT-versus Peyer’s patch-mediated mucosal immunity. Nat Rev Immunol 4:699–710
79. Kristensson K (2011) Microbes’ roadmap to neurons. Nat Rev Neurosci 12(6):345–357
80. Kristensson K, Olsson Y (1971) Uptake of exogenous proteins in mouse olfactory cells. Acta Neuropathol 19(2):145–154
81. Laing JM, Aurelian L (2008) DeltaRR vaccination protects from KA-induced seizures and neuronal loss through ICP10PK-mediated modulation of the neuronal-microglial axis. Genet Vaccines Ther 6:1
82. Lansley AB, Martin GP (2001) Nasal drug delivery. In: Hillery AM, Lloyd AW, Swarbrick J (eds)Drug delivery and targeting. CRC Press, Boca Raton, pp 237–268
83. Lee ST, Chu K, Jung KH, Kim JH, Huh JY, Yoon H, Park DK, Lim JY, Kim JM, Jeon D, Ryu H, Lee SK, Kim M, Roh JK (2012) miR-206 regulates brain-derived neurotrophic factor in Alzheimer disease model. Ann Neurol 72(2):269–27
84. Li Y, Field PM, Raisman G (2005) Olfactory ensheathing cells and olfactory nerve fi broblasts maintain continuous open channels for regrowth of olfactory nerve fi bres. Glia 52(3):245–251
85. Lochhead JJ, Thorne RG (2012) Intranasal delivery of biologics to the central nervous system. Adv Drug Deliv Rev 64(7):614–628
86. Matsuoka Y, Gray AJ, Hirata-Fukae C, Minami SS, Waterhouse EG, Mattson MP, LaFerla FM, Gozes I, Aisen PS (2007) Intranasal NAP administration reduces accumulation of amyloid peptide and tau hyperphosphorylation in a transgenic mouse model of Alzheimer’s disease at early pathological stage. J Mol Neurosci 31(2):165–170
87. Merkus P, Guchelaar HJ, Bosch DA, Merkus FW (2003) Direct access of drugs to the human brain after intranasal drug administration? Neurology 60(10):1669–1671
88. Mery S, Gross EA, Joyner DR, Godo M, Morgan KT (1994) Nasal diagrams: a tool for recording the distribution of nasal lesions in rats and mice. Toxicol Pathol 22:353–372
89. Miller DS (2010) Regulation of P-glycoprotein and other ABC drug transporters at the blood-brain barrier. Trends Pharmacol Sci 31(6):246–254
90. Miller (2013) The promise and perils of oxytocin. Science 339:267–269
91. Neuwelt E, Abbott NJ, Abrey L, Banks WA, Blakley B, Davis T, Engelhardt B, Grammas P, Nedergaard M, Nutt J, Pardridge W, Rosenberg GA, Smith Q, Drewes LR (2008) Strategies to advance translational research into brain barriers. Lancet Neurol 7(1):84–96
92. Powell KJ, Hori SE, Leslie R, Andrieux A, Schellinck H, Thorne M, Robertson GS (2007) Cognitive impairments in the STOP null mouse model of schizophrenia. Behav Neurosci 121(5):826–835
93. Reese TS, Karnovsky MJ (1967) Fine structural localization of a blood-brain barrier to exogenous peroxidase. J Cell Biol 34(1):207–217
94. Reitz M, Demestre M, Sedlacik J, Meissner H, Fiehler J, Kim SU, Westphal M, Schmidt NO (2012) Intranasal delivery of neural stem/progenitor cells: a noninvasive passage to target intra-cerebral glioma. Stem Cells Transl Med 1(12):866–873
95. Rennels ML, Gregory TF, Blaumanis OR, Fujimoto K, Grady PA (1985) Evidence for a ‘paravas-cular’ fl uid circulation in the mammalian central nervous system, provided by the rapid distribution of tracer protein throughout the brain from the subarachnoid space. Brain Res 326(1):47–63
96. Renner DB, Frey WH II, Hanson LR (2012a) Intranasal delivery of siRNA to the olfactory bulbs of mice via the olfactory nerve pathway. Neurosci Lett 513(2):193–197
97. Renner DB, Svitak AL, Gallus NJ, Ericson ME, Frey WH II, Hanson LR (2012b) Intranasal delivery of insulin via the olfactory nerve pathway. J Pharm Pharmacol 64(12):1709–1714
98. Rojanasakul Y, Wang LY, Bhat M, Glover DD, Malanga CJ, Ma JK (1992) The transport barrier of epithelia: a comparative study on membrane permeability and charge selectivity in the rabbit. Pharm Res 9(8):1029–1034
99. Ronaldson PT, Babakhanian K, Bendayan R (2007) Drug transport in the brain. In: You G, Morris ME (eds) Drug transporters: molecular characterization and role in drug disposition. Wiley-Interscience, Hoboken, pp 411–461
100. Ross TM, Martinez PM, Renner JC, Thorne RG, Hanson LR, Frey WH II (2004) Intranasal administration of interferon beta bypasses the blood-brain barrier to target the central nervous system and cervical lymph nodes: a non-invasive treatment strategy for multiple sclerosis. J Neuroimmunol 151(1–2):66–77
101. Sakane T, Akizuki M, Taki Y, Yamashita S, Sezaki H, Nadai T (1995) Direct drug transport from the rat nasal cavity to the cerebrospinal fl uid: the relation to the molecular weight of drugs. J Pharm Pharmacol 47(5):379–381
102. Schaefer ML, Bottger B, Silver WL, Finger TE (2002) Trigeminal collaterals in the nasal epithelium and olfactory bulb: a potential route for direct modulation of olfactory information by trigeminal stimuli. J Comp Neurol 444(3):221–226
103. Schley D, Carare-Nnadi R, Please CP, Perry VH, Weller RO (2006) Mechanisms to explain the reverse perivascular transport of solutes out of the brain. J Theor Biol 238(4):962–974
104. Schuenke M, Schulte E, Schumacher U (2010) Head and neuroanatomy. Atlas of anatomy. Thieme, Stuttgart
105. Scremin OU (2004) Cerebral vascular system. In: Paxinos G (ed) The rat nervous system. Elsevier, Inc., San Diego, pp 1167–1202
106. Sezaki H (1995) Mucosal penetration enhancement. J Drug Target 3(3):175–177
107. Shiryaev N, Jouroukhin Y, Giladi E, Polyzoidou E, Grigoriadis NC, Rosenmann H, Gozes I (2009) NAP protects memory, increases soluble tau and reduces tau hyperphosphorylation in a tauopa-thy model. Neurobiol Dis 34(2):381–388
108. Steinke A, Meier-Stiegen S, Drenckhahn D, Asan E (2008) Molecular composition of tight and adherens junctions in the rat olfactory epithelium and fi la. Histochem Cell Biol 130(2): 339–361
109. Stevens J, Ploeger BA, van der Graaf PH, Danhof M, de Lange EC (2011) Systemic and direct nose-to-brain transport pharmacokinetic model for remoxipride after intravenous and intranasal administration. Drug Metab Dispos 39(12):2275–2282
110. Stoop R (2012) Neuromodulation by oxytocin and vasopressin. Neuron 76(1):142–159
111. Szentistvanyi I, Patlak CS, Ellis RA, Cserr HF (1984) Drainage of interstitial fl uid from different regions of rat brain. Am J Physiol 246(6 Pt 2):F835–F844
112. Thiebaud N, Menetrier F, Belloir C, Minn A-L, Neiers F, Artur Y, Le Bon A-M, Heydel J-M (2011)Expression and differential localization of xenobiotic transporters in the rat olfactory neuro-epithelium. Neurosci Lett 505:180–185
113. Thorne RG, Emory CR, Ala TA, Frey WH II (1995) Quantitative analysis of the olfactory pathway for drug delivery to the brain. Brain research 692(1–2):278–282
114. Thorne RG, Frey WH II (2001) Delivery of neurotrophic factors to the central nervous system: pharmacokinetic considerations. Clin Pharmacokinet 40(12):907–946
115. Thorne RG, Hanson LR, Ross TM, Tung D, Frey WH II (2008) Delivery of interferon-beta to the monkey nervous system following intranasal administration. Neuroscience 152(3):785–797
116. Thorne RG, Hrabetova S, Nicholson C (2004a) Diffusion of epidermal growth factor in rat brain extracellular space measured by integrative optical imaging. J Neurophysiol 92(6):3471–3481
117. Thorne RG, Pronk GJ, Padmanabhan V, Frey WH II (2004b) Delivery of insulin-like growth factor- I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration. Neuroscience 127(2):481–496
118. Tucker D (1971) Nonolfactory responses from the nasal cavity: Jacobson’s organ and the trigeminal system. In: Biedler LM (ed) Handbook of sensory physiology, vol 4. Springer, New York, pp 151–181
119. van Velthoven CT, Sheldon RA, Kavelaars A, Derugin N, Vexler ZS, Willemen HL, Maas M, Heijnen CJ, Ferriero DM (2013) Mesenchymal stem cell transplantation attenuates brain injury after neonatal stroke. Stroke 44(5):1426–1432
120. Wang P, Olbricht WL (2011) Fluid mechanics in the perivascular space. J Theor Biol 274(1):52–57
121. Wei N, Yu SP, Gu X, Taylor TM, Song D, Liu XF, Wei L (2013) Delayed intranasal delivery of hypoxic-preconditioned bone marrow mesenchymal stem cells enhanced cell homing and therapeutic benefi ts after ischemic stroke in mice. Cell Transplant 22(6):977–991
122. Wolburg H, Wolburg-Buchholz K, Sam H, Horvat S, Deli MA, Mack AF (2008) Epithelial and endothelial barriers in the olfactory region of the nasal cavity of the rat. Histochem Cell Biol130(1):127–140
123. Xiao C, Davis FJ, Chauhan BC, Viola KL, Lacor PN, Velasco PT, Klein WL, Chauhan NB (2013) Brain transit and ameliorative effects of intranasally delivered anti-amyloid-beta oligomer antibody in 5XFAD mice. J Alzheimers Dis 35(4):777–788
124. Yang JP, Liu HJ, Cheng SM, Wang ZL, Cheng X, Yu HX, Liu XF (2009) Direct transport of VEGF from the nasal cavity to brain. Neurosci Lett 449(2):108–111
125. Yoffey JM, Drinker CK (1938) The lymphatic pathway from the nose and pharynx: the absorption of dyes. J Exp Med 68(4):629–640